Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Net Income (2016 - 2025)

Protalix BioTherapeutics has reported Net Income over the past 16 years, most recently at -$1.1 million for Q4 2025.

  • Quarterly results put Net Income at -$1.1 million for Q4 2025, down 109.77% from a year ago — trailing twelve months through Dec 2025 was -$2.1 million (down 127.77% YoY), and the annual figure for FY2025 was -$2.0 million, down 126.24%.
  • Net Income for Q4 2025 was -$1.1 million at Protalix BioTherapeutics, down from $2.4 million in the prior quarter.
  • Over the last five years, Net Income for PLX hit a ceiling of $19.3 million in Q2 2023 and a floor of -$18.6 million in Q4 2023.
  • Median Net Income over the past 5 years was -$3.2 million (2022), compared with a mean of -$2.1 million.
  • Biggest five-year swings in Net Income: crashed 2179.87% in 2021 and later soared 462.56% in 2023.
  • Protalix BioTherapeutics' Net Income stood at -$6.6 million in 2021, then soared by 51.47% to -$3.2 million in 2022, then plummeted by 478.79% to -$18.6 million in 2023, then soared by 160.7% to $11.3 million in 2024, then plummeted by 109.77% to -$1.1 million in 2025.
  • The last three reported values for Net Income were -$1.1 million (Q4 2025), $2.4 million (Q3 2025), and $164000.0 (Q2 2025) per Business Quant data.